IL10 and neoplasm: More importantly, anti-mouse PD-1 mAb treatment does not affect tumor growth when used in preclinical tumor models, indicating that these animal models do not recapitulate the heterogeneous T-cell responses of human cancers treated with anti-PD-1/PD-L1 therapy [25]. Blocking IL-10 signaling enhances anti-PD-1 induced tumor antigen-specific CD8+ T cell functions in metastatic melanoma patients [15].